Indication: Systemic Sclerosis Enrollment Status: Pre-Enrollment Protocol: CVAY736S12201 Drug: Ianalumab Sponsor: Novartis Description: A randomized, double-blind, parallel group, placebo-controlled multicenter
Indication: Systemic Lupus Erythematosus Enrollment Status: Pre-Enrollment Protocol: M23-699 Drug: Upadacitinib Sponsor: Abbvie Description: A Phase 3 Program to Evaluate
Indication: Sjogren’s Syndrome Enrollment Status: Enrollment Open Protocol: HZNP-DAZ-301, HZNP-DAZ-301 HZNP-DAZ-304 “Oasis” Drug: Dazodalibep Sponsor: Horizon/Amgen Description: 301 Description: A
Indication: Rheumatoid Arthritis Enrollment Status: Pre-Enrollment Protocol: IMVT-1402-2601 Drug: IMVT-1402 Sponsor: Immunovant Description: A Phase 2b, Multicenter, Double-blind, Placebo-controlled Randomized
Indication: Psoriatic Arthritis Enrollment Status: Enrollment Open Protocol: CNTO1959PSA4002-STAR Drug: Guselkumab Sponsor: Janssen Description: A Phase 4, Multicenter, Randomized, Double-blind,
Indication: Psoriatic Arthritis Enrollment Status: Enrollment Open Protocol: TAK279PsA3001 Drug: Bimekizumab Sponsor: UCB Pharma Description: PA0016- A Multicenter, Randomized, Double-Blind,
Indication: Psoriatic Arthritis Enrollment Status: Enrollment Open Protocol: PA0016 “Be Bold” Drug: Zasocitinib Sponsor: Takeda Description: A Multi-Center, Randomized, Double-Blind,
Indication: Polymyalgia Rheumatica Enrollment Status: Enrollment Closed Protocol: CAIN457C22301+Extension Drug: COSENTYX® (secukinumab) Sponsor: Novartis Description: Novartis Pharmaceutical Trial entitled: A
Indication: Cutaneous Lupus Erythematosus Enrollment Status: Pre-Enrollment Protocol: IMVT-1402-2701 Drug: IMVT-1402 Sponsor: Immunovant Description: A Phase 2b, Randomized, Double-blind, Placebo-controlled
